CRBU Stock Plummets 35% Premarket on RBC Target Cut
Caribou Biosciences (CRBU) shares fell over 35% in pre-market trading after RBC Capital Markets slashed its price target by 90% following the company's decision to scale back its CAR-T cancer-drug development programs.
Shares of Caribou Biosciences (CRBU) fell more than 35% in pre-market trading on Wednesday after Wall Street sharply reduced its price target, following the biotech company’s decision to scale back its cancer-drug development efforts. If the move holds after the open, CRBU would trade at a new 52-week low.